Autolus Therapeutics plc filed a Current Report on Form 8-K on November 10, 2026, announcing its financial results for the quarter ended September 30, 2026, and furnishing an updated corporate presentation used in connection with a same-day conference call.

Key Highlights

  • Reporting period: Financial results cover the quarter ended September 30, 2026.
  • Press release furnished: A press release dated November 10, 2026, was furnished as Exhibit 99.1 and incorporated by reference.
  • Corporate presentation: An updated corporate presentation dated November 10, 2026, was furnished as Exhibit 99.2 under Regulation FD Disclosure (Item 7.01).
  • Conference call: The company disclosed it held a conference call on November 10, 2026, to discuss its Q3 2026 results.
  • Signing officer: The report was signed by Christian Itin, Ph.D., Chief Executive Officer, on November 10, 2026.
  • Filing status: The information in Items 2.02 and 7.01, including the exhibits, is furnished and "shall not be deemed 'filed'" for purposes of Section 18 of the Securities Exchange Act of 1934.

Autolus Q3 2026 Results Announcement and Regulation FD Presentation

Autolus Therapeutics plc (NASDAQ:AUTL), incorporated in England and Wales and headquartered in London, filed a Form 8-K with the U.S. Securities and Exchange Commission on November 10, 2026. According to the filing, the company announced its financial results for the quarter ended September 30, 2026, and provided a corporate update. The press release containing those results was furnished as Exhibit 99.1 and incorporated by reference into the filing.

The filing also disclosed, under Item 7.01 (Regulation FD Disclosure), that in connection with a conference call held on November 10, 2026, the company utilized an updated corporate presentation, furnished as Exhibit 99.2. The filing notes that the information in both items is being "furnished" rather than "filed," meaning it is not subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into other company filings under the Securities Act of 1933 or the Exchange Act except as expressly set forth by specific reference.

The American Depositary Shares of Autolus Therapeutics, each representing one ordinary share with a nominal value of $0.000042 per share, are listed on The Nasdaq Global Select Market under the trading symbol AUTL. The report was signed on behalf of the registrant by Christian Itin, Ph.D., in his capacity as Chief Executive Officer.

What Was Disclosed

Autolus Therapeutics plc furnished its Q3 2026 earnings press release and an updated corporate presentation via Form 8-K on November 10, 2026. Both items are furnished, not filed, and cover the quarter ended September 30, 2026.